{"ticker": {"uuid": "2df93a09-d5de-417a-9cf4-05344c80107f", "symbol": "ANNX", "name": "Annexon\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "How Investors Are Reacting To Annexon (ANNX) Phase 3 Tanruprubart Win And Vonaprument Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQUkt6Y2dSNTFXekxmWXZ5bldhajU1OGU4YWR5UmltMEpwWEZBdHlabzc5c3p6Um91bHQ2ZHBoOFJTV1FEaUNYMWlpVUFJb21YRDVEcWFjaEFXSHpvU1FsUVpFZUdJaFdoUVF2eUN4OTh5VzZSMk5mWm0tTVBOekN6ZzVTMGNkZXMwcXBhZ3EyV09KMHJWamUyaFBYSlVVOFhwaE13eQ?oc=5", "source_name": "Market source", "published_at": "2026-07-16T23:17:41+00:00", "published_display": "16 Jul 2026 23:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to two new non-executive employees under the terms of its 2022 Employment Inducement Award Plan. These equity awards, approved on July 12, 2026, consist of options to purchase 335,000 shares of common stock with an exercise", "url": "https://ca.finance.yahoo.com/news/annexon-reports-inducement-grants-employees-200500920.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-16T19:41:51", "published_display": "16 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two New Annexon Employees Receive 10-Year Options at $6.50", "summary": "Annexon (Nasdaq: ANNX) has granted stock options for an aggregate of 335,000 common shares to two new non-executive employees under its 2022 Employment Inducement Award Plan. The options have a ten-year term with an exercise price of $6.50 per share, which was the closing price o", "url": "https://www.stocktitan.net/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-u3bwk87p8j6b.html", "source_name": "Stock Titan", "published_at": "2026-07-16T19:41:51", "published_display": "16 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) filer Thomas Wiggans eyes 2,000-share NASDAQ stock sale", "summary": "Thomas Wiggans, a shareholder in Annexon (ANNX), has filed a notice for the proposed sale of 2,000 common shares via Fidelity Brokerage Services LLC on NASDAQ, with an indicated value of $12,630.01. This planned sale follows a previous sale of 1,000 common shares by Wiggans on Ju", "url": "https://www.stocktitan.net/sec-filings/ANNX/144-annexon-inc-sec-filing-7931b87054a6.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:17:07", "published_display": "15 Jul 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $27", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPQV9VS21WZnpxT0RHVUNGTVdFZ1o5cGNHdmoxQnJEbUFsMkxZTUs4QWNaZFhSclY3TTc5TGNzV2xaSnZ3QnBSckFlT01HcmpRNW9ybWU2VnMwcXlEUFhVdTB4X0lmdVdtVXpzWm9QSDVGcG82R1VaS3p1VnR6VWxDM3FCWklPMHZoR3gtY1BJZzZFYVRGZHhWdXdmS3hkc24wNjdtWWJISVlWQ0Z0Mmh3VQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T16:16:16+00:00", "published_display": "15 Jul 2026 16:16", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham raises Annexon Biosciences stock price target to $25 on trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOaVhPUGVSQ000SF8yLXozdFdJODdWcDlscE1JeDNrZk9tcEFaeDJIaVlfampudUZNNm5HR2F2SFc1MTEwLUhLcGNaMU1wZ0lpWl9NUEVVc1UzckhQRlVZRkM2TGZQYUM1NlVRUGVLWGE0cFhsaGhCWEN4bktSOFJvQWFQRFo5YlRXZkpkREU0dmM3Z0hhV25iT05hR2duUHphR3MwMVJkSF9NWVVYajUwWUVUYkY0bHFaOXA4bjUwOTdsbzhRNEJBOA?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T12:50:23+00:00", "published_display": "15 Jul 2026 12:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANNX Maintained by Needham -- Price Target Raised to $25", "summary": "Needham analyst Joseph Stringer maintained a 'Buy' rating on Annexon (ANNX) and significantly raised the price target from $11.00 to $25.00, reflecting strong confidence in the company's growth potential. Despite a low GF Score of 34/100, primarily due to profitability challenges", "url": "https://www.gurufocus.com/news/8959878/annx-maintained-by-needham-price-target-raised-to-25", "source_name": "GuruFocus", "published_at": "2026-07-15T12:17:07", "published_display": "15 Jul 2026 12:17", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) Presents Key Findings on Vision Preservation at A", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQdnNOUEQtR2NNZFA1SUxIRnZCVEQ2aHo4azhjYjhrdERFVEtvbFNBeTRGSjJGUGM2RWhSS1dwMTVxQS1IYkJZU2VpTHJsTUZvWVNkd1poSFdiWndYaWZ1bHVMa0hNa2MtSklUd0VOMHp0dDRCUGFVOWUzN19HdkhRSXFIZG51VldSUFNZRzNVZVVGNTFaX2paenNTS1kwNl93ZF9xV1Ztc09YRkxFQVQwU2hVOW1rTll6eTllRHQ3bi1oQQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T03:35:18+00:00", "published_display": "15 Jul 2026 03:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon to present data on vonaprument for macular degeneration By Investing.com", "summary": "Annexon Inc. is set to present Phase 2 ARCHER trial data on its drug candidate, vonaprument, for geographic atrophy at the American Society of Retina Specialists 44th Annual Scientific Meeting. This data will inform patient selection for the ongoing Phase 3 ARCHER II trial, which", "url": "https://ca.investing.com/news/stock-market-news/annexon-to-present-data-on-vonaprument-for-macular-degeneration-93CH-4733825", "source_name": "Investing.com Canada", "published_at": "2026-07-15T01:12:20", "published_display": "15 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon to present data on vonaprument for macular degeneration", "summary": "Annexon Inc. will present data from its Phase 2 ARCHER trial for vonaprument, a treatment for geographic atrophy, at the American Society of Retina Specialists meeting. The data will help select patients for the ongoing Phase 3 ARCHER II trial, which completed enrollment in July ", "url": "https://www.investing.com/news/company-news/annexon-to-present-data-on-vonaprument-for-macular-degeneration-93CH-4791616", "source_name": "Investing.com", "published_at": "2026-07-14T20:16:05", "published_display": "14 Jul 2026 20:16", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026", "summary": "Annexon, Inc. announced an oral presentation at the American Society of Retina Specialists 44th Annual Scientific Meeting regarding the neuroprotective effect of vonaprument. The presentation will highlight baseline characteristics from the Phase 2 ARCHER trial associated with be", "url": "https://www.globenewswire.com/news-release/2026/07/14/3327265/0/en/annexon-to-present-phase-2-archer-baseline-characteristics-associated-with-confirmed-best-corrected-visual-acuity-15-letter-loss-in-patients-with-geographic-atrophy-at-asrs-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T20:12:20", "published_display": "14 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon to present baseline factors tied to 15-letter vision loss in AMD", "summary": "Annexon (NASDAQ: ANNX) is set to deliver an oral presentation at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, detailing Phase 2 ARCHER trial data for vonaprument in dry age-related macular degeneration (AMD) with geographic atrophy (GA). The p", "url": "https://www.stocktitan.net/news/ANNX/annexon-to-present-phase-2-archer-baseline-characteristics-7x0tnimvd7sl.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:12:20", "published_display": "14 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Annexon, Inc. SEC Filing", "summary": "This article details a Form 144 SEC filing by Annexon, Inc. (ANNX), indicating a proposed sale of securities. The filing shows a sale of 1000 common shares by an individual with Fidelity Brokerage Services LLC, acquired through a stock option exercise, with an aggregate market va", "url": "https://www.stocktitan.net/sec-filings/ANNX/144-annexon-inc-sec-filing-680ee3e00950.html", "source_name": "Stock Titan", "published_at": "2026-07-14T18:12:19", "published_display": "14 Jul 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon: Perfect Complement To A Speculative Biotech Portfolio (NASDAQ:ANNX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQOFgwd2hKMUY1Q2dQVTBtZFFCS1M5MkhqUHJyS3V1MzUxMDRNYjVycXp4R3QtQVUweXkwUVNqUXlLdHlFTzBkeW5HczI0R0xEMkJ6ZGtJUXZOcTEyQTV4cVI0Z05CWFY1SEZVY1k0SmdRVkxOMk9Fc0cydjZSYXJvcGZtSE9VTzVnS1E2VzBvVmdwMTU4X21FRGJadnVLWTN6T000VA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T09:43:52+00:00", "published_display": "14 Jul 2026 09:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Annexon stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQdDVtVFRkTkxSY2FsYzc2ald2RlVnQTdSRlJNNEhxbWJubmpfMkRlcmhZVXBndlZyX3BrVW5MZm5abmxUZnRPRmdPMDdBb045ZzhxUTdkRS1ZRndwNFlYWV9oUGQ1UXM5UHdTUGVtRzdoNkZkSjJOVVpwNklUM0hvZGpfdXdSdDJEYzVrZlpuYXI1NWp6M3AzWnc4c3Z4ZG9uWVB5X3FjT3BVVUl0OURpLW5SYjZuNjJU?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T14:38:13+00:00", "published_display": "13 Jul 2026 14:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to book forward of Annexon, Inc. \u2013 NASDAQ:ANNX", "summary": "This article provides financial information for Annexon, Inc. (NASDAQ: ANNX), specifically focusing on its \"Price to book forward\" metric. The content appears to be a financial data page from TradingView, displaying the company's stock exchange listing and current market status. ", "url": "https://www.tradingview.com/symbols/NASDAQ-ANNX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T01:09:18", "published_display": "11 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redmile Group (ANNX) reports 9.9% stake; RedCo II Offshore at 5.5%", "summary": "Redmile Group, LLC, and affiliated persons, including Jeremy C. Green, have reported a beneficial ownership stake of 9.9% in Annexon, Inc. (ANNX), comprising 17,918,459 shares. Additionally, RedCo II Offshore SPV LLC disclosed a 5.5% stake with 9,802,458 shares. These figures inc", "url": "https://www.stocktitan.net/sec-filings/ANNX/schedule-13g-a-annexon-inc-amended-passive-investment-disclosure-dd7dea6f78a8.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:40:49", "published_display": "09 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC reports 11.9% stake in Annexon (NASDAQ: ANNX)", "summary": "FMR LLC has filed a Schedule 13G/A, disclosing a beneficial ownership of 19,518,496.35 shares of Annexon (NASDAQ: ANNX) common stock, representing an 11.9% stake as of June 30, 2026. This filing indicates a passive investment intent, with FMR LLC holding sole dispositive power ov", "url": "https://www.stocktitan.net/sec-filings/ANNX/schedule-13g-a-annexon-inc-amended-passive-investment-disclosure-ae6ac97146ef.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:40:14", "published_display": "08 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "Annexon presented key updates on its clinical programs at the Goldman Sachs 47th Annual Global Healthcare Conference 2026, focusing on vonaprument for geographic atrophy (GA). The company anticipates pivotal Phase III data in Q4 2026, with vision preservation as the primary endpo", "url": "https://quartr.com/events/annexon-annx-goldman-sachs-47th-annual-global-healthcare-conference-2026_FLVYElEn", "source_name": "Quartr", "published_at": "2026-07-08T12:11:15", "published_display": "08 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Annexon\u2019s Shift Into Russell Growth Indices Recast Its Core Equity Story for Investors (ANNX)?", "summary": "Annexon, Inc. (ANNX) recently shifted from Russell value to growth indices in late June 2026, which impacts its perceived style profile and investor exposure. While this reclassification mainly affects who holds the stock, Annexon's core investment narrative remains focused on it", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-annx/annexon/news/does-annexons-shift-into-russell-growth-indices-recast-its-c", "source_name": "Simply Wall Street", "published_at": "2026-07-08T11:40:14", "published_display": "08 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANNX - Annexon Inc Options", "summary": "This page provides detailed financial and stock options information for Annexon Inc (ANNX). It includes key metrics such as market capitalization, income, sales, EPS, various financial ratios, insider and institutional ownership, and stock performance data. The data indicates rec", "url": "https://finviz.com/stock?t=ANNX&ty=oc&ta=1&p=m&ov=chain_date&e=2026-06-18", "source_name": "Finviz", "published_at": "2026-07-06T23:10:35", "published_display": "06 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $11", "summary": "Needham has reiterated its Buy rating for Annexon (ANNX.US) and maintained a target price of $11. This indicates continued confidence in the company's stock performance from the analyst firm.", "url": "https://www.moomoo.com/news/post/72399775/needham-maintains-annexon-annxus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-07-02T22:13:20", "published_display": "02 Jul 2026 22:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon, Inc.(NasdaqGS: ANNX) dropped from Russell 2000 Value Benchmark", "summary": "Annexon, Inc. (NasdaqGS: ANNX) has been removed from the Russell 2000 Value Benchmark. This news follows several recent re-benchmarking announcements, including its addition to the Russell 2500 Growth and Russell 2000 Growth Benchmarks, and also being dropped from the Russell Mic", "url": "https://www.marketscreener.com/news/annexon-inc-nasdaqgs-annx-dropped-from-russell-2000-value-benchmark-ce7f5fdfd88df724", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:09:26", "published_display": "29 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon, Inc. Actuals & Estimates (NASDAQ:ANNX)", "summary": "This article provides an overview of Annexon, Inc. (NASDAQ:ANNX) financial actuals and estimates, including its current stock price, market capitalization, and analyst forecasts. It also covers historical stock performance, earnings reports, and other key financial data. Investor", "url": "https://www.tradingview.com/symbols/NASDAQ-ANNX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:10:40", "published_display": "26 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon, Inc.'s (NASDAQ:ANNX) Profit Outlook", "summary": "This article analyzes the profit outlook for Annexon, Inc. (NASDAQ:ANNX) based on analyst forecasts. It discusses how the company is expected to transition from its current loss-making status to profitability and the projected financial performance over the coming years according", "url": "https://news.futunn.com/en/post/74965567/annexon-inc-s-nasdaq-annx-profit-outlook", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-24T19:39:51", "published_display": "24 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) Jefferies Global Healthcare Conference 2026 Summary", "summary": "This article summarizes Annexon's (ANNX) presentation at the Jefferies Global Healthcare Conference 2026, highlighting its strategic focus on pioneering C1q inhibition for neuroinflammatory diseases. Key points include late-stage development programs for Guillain-Barr\u00e9 syndrome (", "url": "https://quartr.com/events/annexon-inc-annx-jefferies-global-healthcare-conference-2026_FLVYElEG", "source_name": "Quartr", "published_at": "2026-06-22T17:09:54", "published_display": "22 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) AGM 2026 Summary", "summary": "Annexon's 2026 AGM summarized highlights from the company's annual meeting on June 11, 2026. Key points included a financial performance review indicating a cash runway into Q2 2027 and updates to the board and executive committee, noting the retirement of Tom Wiggans. The summar", "url": "https://quartr.com/events/annexon-inc-annx-agm-2026_FLVYEJqt", "source_name": "Quartr", "published_at": "2026-06-22T04:41:43", "published_display": "22 Jun 2026 04:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Inc (ANNX) Institutional Confidence", "summary": "This article examines the institutional confidence in Annexon Inc (ANNX) by detailing the shareholdings and activity of several major institutional investors. It highlights significant changes in holdings by firms like Redmile Group, Alerce Investment Management, and Adage Capita", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-annx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:46", "published_display": "18 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Inc (ANNX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Annexon Inc (ANNX), including analyst ratings, target prices, and EPS estimates. Based on 11 analysts, the stock has a \"Buy\" trend with a target price of $14.50, representing an upside of over 220%. The report also includes past and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-annx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:36:46", "published_display": "18 Jun 2026 02:36", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Inc (ANNX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Annexon Inc.'s (ANNX) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and reports no data available for historical dividend payments or stock splits. The page primarily fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-annx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:40", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Inc (ANNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Annexon Inc (ANNX), covering its support, resistance, indicators, and moving averages. According to the analysis, relevant data for support and resistance have not been disclosed, while the technical indicators show mixed signals with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-annx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T22:39:46", "published_display": "17 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (NASDAQ: ANNX) EVP exercises stock options, lifts stake to 184,807 shares", "summary": "Annexon, Inc. EVP Ted Yednock exercised stock options to acquire 30,646 common shares at an exercise price of $1.8501 per share on June 11, 2026. This transaction increased his direct ownership to 184,807 shares. The options were fully vested and exercisable, representing a routi", "url": "https://www.stocktitan.net/sec-filings/ANNX/form-4-annexon-inc-insider-trading-activity-aaa3edc97803.html", "source_name": "Stock Titan", "published_at": "2026-06-17T08:39:24", "published_display": "17 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new Annexon hires receive options on 705,000 shares", "summary": "Annexon (Nasdaq: ANNX) has granted stock options for 705,000 shares to two new non-executive employees under its 2022 Employment Inducement Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.64 per share, a ten-year term, and a", "url": "https://www.stocktitan.net/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-dn2okxqikwg4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:10:10", "published_display": "16 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) director William Waddill receives 65,000 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWG9oSENkSmt3bUpiTGZ0WXk3SDEyZHpXbmM4SGl5SmR0M3YxZEx3MkEybENGLUNMTTk0ald5aWdyUVBnbnlyNmh5bW82ZUVjRXNWektZa1lBZXVMTER4YkZWeHl4eE01NFdJRHpWZjY1NnZ4ODNpSS1oWG9ob3o5Y28tN3pzVnQzQXliNHZYY3puenpCWlVyQThPaVB3dXRVaDVvT2NXNFo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) grants director Jung Choi 65,000 stock options at $4.70", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPcjI0MU84LTJpYXRaZzk0cjJDYW5BTDJ2WnRBaFVpZlJrZGJqbzNieTdfR0w1XzA3eG1UUndWbldCQVN1emdyYk1TV3pKS1U3aFJGaldBSVNfLXhjbUJKZ05tRHJpc1A4NVhJS1ZWUDlRSE9jOElJdEx3M0lWQlRkWFJsSEpSLUhmb21iX2dvQXlxVk93MXZTb1k2M0JxT1V6UmlFTkR2cUc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) director Bettina Cockroft awarded 65,000 stock options at $4.70", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOMi11RTVKU05ybGNVZkFPenRScURDS0NwOVluTWR0dE5fYjBhTWkwTVQ1VE5TZmo0T0M3WVYyMHVNd2U1TUNKd3E5X2dWMS1GVEpHbnppN3BnT3JHZmpCdWgzSi1xdGxCaUVRMk8xWUxScUdqUW52RmRnbE1aZk5aVVJDVC1HOVQxOW0yZ3EzZXJTNFJ6aEkzNmFkOWhDWWtGWkRTTFMyRXQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Eyes \u2018Win Season\u2019 With Q4 Vision Trial Data, GBS Filings Ahead", "summary": "", "url": "https://finance.yahoo.com/m/cc1b8a8c-417c-3307-86b7-ca1eade936f5/annexon-eyes-%E2%80%98win-season%E2%80%99.html", "source_name": "MarketBeat", "published_at": "2026-06-09T13:06:41+00:00", "published_display": "09 Jun 2026 13:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout", "summary": "", "url": "https://finance.yahoo.com/m/53971b69-6329-3d1f-a36f-1fb8267f5acb/annexon-maps-3-big-pipeline.html", "source_name": "MarketBeat", "published_at": "2026-06-04T07:07:07+00:00", "published_display": "04 Jun 2026 07:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Insider Bought Shares Worth $3,319,019, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/annexon-insider-bought-shares-worth-212921469.html", "source_name": "MT Newswires", "published_at": "2026-05-29T21:29:21+00:00", "published_display": "29 May 2026 21:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon to Participate in Upcoming June Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/news/annexon-participate-upcoming-june-investor-120000016.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T12:00:00+00:00", "published_display": "27 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon CEO Douglas Love to speak at Jefferies and Goldman Sachs in June", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQaDdGMGZ5a1pmME94QTAwb3kxeVY4M1lpOHI1Y1A5TWY2QXZGTFg0THRhWmNQbGpwbGhJNUF4V0J4bXdJTWpzdTl1VzlNZnQ5M0tqcXptMC12WFF6eEQwVVhzNnZVTHlVeGpnek8yLTVyVjZfSzk1eldlTFlmMGhxU1hiX3M2bXRIMkhFMi1QaUtLcVpWM2FMRmZNaFJxSFdDa0VzTDF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference", "summary": "", "url": "https://finance.yahoo.com/m/01b0e3a3-0fc9-342d-84c7-c9c2abf55d9b/annexon-highlights-q4.html", "source_name": "MarketBeat", "published_at": "2026-05-14T08:05:47+00:00", "published_display": "14 May 2026 08:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Goldman Sachs Initiates Annexon at Neutral With $7 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/goldman-sachs-initiates-annexon-neutral-112947244.html", "source_name": "MT Newswires", "published_at": "2026-05-12T11:29:47+00:00", "published_display": "12 May 2026 11:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxNU3dZcUI0ZHk2UFB5T2MyYXUzdEp3SGdPNnF6WGdrd3MtYWFwVVZkaVMxSDUwbWpyMldaM045MUFHcmFrUThLY0FtR0JiRWYzbl9MOWtTMmlDSHJIRTN1bk53VklMQlVFMXZTclAzOW9welBHdHQySHpmTF9odG9saGc5MHJpVUJBVTFIaU5qZlFLNDBSZ0dDbXdBNzlYTjkyTEpyRDdtMWZXZGk1dmx4dEpYdDdlakpNdVJWSmpqNTBFVThESjFOVEZ1TzV1UkRWVldzLUNtMlZCWlhxa19pZ29OVHg5eDlVRHFiS0VqUGRaSUpnU0pMRUhwaXNwUll3MVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon CEO to speak May 13; webcast replay stays up 30 days", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOLWRqdWZPcExzeHZlSDZPZ3VzQmV0OFY0a2lZRl9yZDRieEpId0xfLXR2aGY1dW1zWlM4aGFFelBlRm9Eanh3VHltMGRab0M3c1pfclNSbUlTb3E3WjlqYzdkMTZVVTJHa3FZWVZGWVVqVUxLbXdlRmVWZGo5VlNoZ2tEbkF6SDYwdGtoVmtPdk5NeHJHSVBWLVV5X0RBa25kRmZJZFJ2UlE3dUs3bWdyTFM2X05FMXZNaHVj?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPMjBZWjl4UGJXUW4xSmkzVVNEenN6eEJxbDNyV3d0S0xEb1dmRmtGMV9IeEFHQmxwZXo2a2hRd3QtcDhqRDdTMHJmeWJ1RGFuZU1PMzlSRUJzU1pINVJHd2Ffd0VZdjBEa2M3bFhGUl9SSnVhcTF6V2FIX21DX0JldlExNzVPa0dyZG9RQmJiN2UtbE0?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxObzgtbGM4aGhwLWFOMEFkdG92QlV0YUxJaW4xV1ZZUUdWWkpacXp4ODVjdXVrajFKUm9IaHFEOUhWUGlYV1RfT3lTaHNUNXMwckd0NS01dDJYcXpidUltVkU1RldNWEZLenZKc0lmRlEzUE9vRXhnT0lpaVpMVXhlcjd5THVlZF82T1lsZVVEYjRCUVZ0THZWVDV2Z2dCcUNlWjR5MXZTS1AwM0gxS1d2eE1nRWd1d1dtbllfMkx6aTA5Zk9SSjExNkFyWVR1Q3g5WmNrZm9qaVNEVEHSAeABQVVfeXFMT2stRnBOQkZYVUFNc1FOVFdqbGdvNTA5aGY3U0cwYVoxN0tCb0JBTERyU3p2b1J0T1FxNXBqeTBwR0U5R09ZY24tSkE4NmNfekFCVDJQcFJTNjY1b21kZWFOazV1eUVDVlRpcmhzWklBaGhaT3FwMDdkT0dGUVBpSUlDbTJYeFJHdFRoZEJkY0FzZXd6WEEzNUVqOE8zaTZSVE5yang0cWpGZmxvZ19zejdvaXBNVnE4alNOSDNpLXdkQ1VQSFFMVHdnRF90TUV2NDlLSWZPd0dhUER3ZWI5RnM?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNMV93b1FHVzU5QzFhbEd0Ym1qQlZyRTBaOGVOT3lIMVhsV1kwNFVobWdUYU4wSXFYNXg4QVgyN2xzY2VqdXpNLS1XRjRuVF9feVY3TThheldGZU5PU1dId05CSkhYX0NrZUc1c191UEFpQ3gtcmhPU1FYQm14a3hHanF0V1N3d21yaVp4Y25DQ2pUb294bXhmT1BvZjN1dHBuNFV2RnZwYm1OM0lma1F1Q3F4N3hSS2xVQXNKVHVsQVFJbXU4TVo2RmxwWlZZUXN1OWJmTDdfRU5Tb2M?oc=5", "source_name": "Investing News Network", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQTmU1cG4xX2ZWX3RWV09pMVdhNjJqQnY4RXVPby1PLXR6Q3phQTN2T3hVeVBBSnhiTUdtLTBzZlBEWWtWTXR0cFRuVmcxdE43N2FKX2tPbTZpbVo5RG50TXRZVjMzX0QwWGVxWFpzaHBUMTl4bVY2Z1YtdnIxS2JwXzRJcDRsWVpxVkZWTk9QZ000Y0lCUDlHdVVxWVJidmVNb1o3eDVmN0tIWTVoQ3VRMGlwbmJyQ3dzeUx3YjZuWUY3QWl4andPanNuaWdlSUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "How Investors Are Reacting To Annexon (ANNX) Phase 3 Tanruprubart Win And Vonaprument Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQUkt6Y2dSNTFXekxmWXZ5bldhajU1OGU4YWR5UmltMEpwWEZBdHlabzc5c3p6Um91bHQ2ZHBoOFJTV1FEaUNYMWlpVUFJb21YRDVEcWFjaEFXSHpvU1FsUVpFZUdJaFdoUVF2eUN4OTh5VzZSMk5mWm0tTVBOekN6ZzVTMGNkZXMwcXBhZ3EyV09KMHJWamUyaFBYSlVVOFhwaE13eQ?oc=5", "source_name": "Market source", "published_at": "2026-07-16T23:17:41+00:00", "published_display": "16 Jul 2026 23:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to two new non-executive employees under the terms of its 2022 Employment Inducement Award Plan. These equity awards, approved on July 12, 2026, consist of options to purchase 335,000 shares of common stock with an exercise", "url": "https://ca.finance.yahoo.com/news/annexon-reports-inducement-grants-employees-200500920.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-16T19:41:51", "published_display": "16 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two New Annexon Employees Receive 10-Year Options at $6.50", "summary": "Annexon (Nasdaq: ANNX) has granted stock options for an aggregate of 335,000 common shares to two new non-executive employees under its 2022 Employment Inducement Award Plan. The options have a ten-year term with an exercise price of $6.50 per share, which was the closing price o", "url": "https://www.stocktitan.net/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-u3bwk87p8j6b.html", "source_name": "Stock Titan", "published_at": "2026-07-16T19:41:51", "published_display": "16 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) filer Thomas Wiggans eyes 2,000-share NASDAQ stock sale", "summary": "Thomas Wiggans, a shareholder in Annexon (ANNX), has filed a notice for the proposed sale of 2,000 common shares via Fidelity Brokerage Services LLC on NASDAQ, with an indicated value of $12,630.01. This planned sale follows a previous sale of 1,000 common shares by Wiggans on Ju", "url": "https://www.stocktitan.net/sec-filings/ANNX/144-annexon-inc-sec-filing-7931b87054a6.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:17:07", "published_display": "15 Jul 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $27", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPQV9VS21WZnpxT0RHVUNGTVdFZ1o5cGNHdmoxQnJEbUFsMkxZTUs4QWNaZFhSclY3TTc5TGNzV2xaSnZ3QnBSckFlT01HcmpRNW9ybWU2VnMwcXlEUFhVdTB4X0lmdVdtVXpzWm9QSDVGcG82R1VaS3p1VnR6VWxDM3FCWklPMHZoR3gtY1BJZzZFYVRGZHhWdXdmS3hkc24wNjdtWWJISVlWQ0Z0Mmh3VQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T16:16:16+00:00", "published_display": "15 Jul 2026 16:16", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham raises Annexon Biosciences stock price target to $25 on trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOaVhPUGVSQ000SF8yLXozdFdJODdWcDlscE1JeDNrZk9tcEFaeDJIaVlfampudUZNNm5HR2F2SFc1MTEwLUhLcGNaMU1wZ0lpWl9NUEVVc1UzckhQRlVZRkM2TGZQYUM1NlVRUGVLWGE0cFhsaGhCWEN4bktSOFJvQWFQRFo5YlRXZkpkREU0dmM3Z0hhV25iT05hR2duUHphR3MwMVJkSF9NWVVYajUwWUVUYkY0bHFaOXA4bjUwOTdsbzhRNEJBOA?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T12:50:23+00:00", "published_display": "15 Jul 2026 12:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANNX Maintained by Needham -- Price Target Raised to $25", "summary": "Needham analyst Joseph Stringer maintained a 'Buy' rating on Annexon (ANNX) and significantly raised the price target from $11.00 to $25.00, reflecting strong confidence in the company's growth potential. Despite a low GF Score of 34/100, primarily due to profitability challenges", "url": "https://www.gurufocus.com/news/8959878/annx-maintained-by-needham-price-target-raised-to-25", "source_name": "GuruFocus", "published_at": "2026-07-15T12:17:07", "published_display": "15 Jul 2026 12:17", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) Presents Key Findings on Vision Preservation at A", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQdnNOUEQtR2NNZFA1SUxIRnZCVEQ2aHo4azhjYjhrdERFVEtvbFNBeTRGSjJGUGM2RWhSS1dwMTVxQS1IYkJZU2VpTHJsTUZvWVNkd1poSFdiWndYaWZ1bHVMa0hNa2MtSklUd0VOMHp0dDRCUGFVOWUzN19HdkhRSXFIZG51VldSUFNZRzNVZVVGNTFaX2paenNTS1kwNl93ZF9xV1Ztc09YRkxFQVQwU2hVOW1rTll6eTllRHQ3bi1oQQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T03:35:18+00:00", "published_display": "15 Jul 2026 03:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon to present data on vonaprument for macular degeneration By Investing.com", "summary": "Annexon Inc. is set to present Phase 2 ARCHER trial data on its drug candidate, vonaprument, for geographic atrophy at the American Society of Retina Specialists 44th Annual Scientific Meeting. This data will inform patient selection for the ongoing Phase 3 ARCHER II trial, which", "url": "https://ca.investing.com/news/stock-market-news/annexon-to-present-data-on-vonaprument-for-macular-degeneration-93CH-4733825", "source_name": "Investing.com Canada", "published_at": "2026-07-15T01:12:20", "published_display": "15 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon to present data on vonaprument for macular degeneration", "summary": "Annexon Inc. will present data from its Phase 2 ARCHER trial for vonaprument, a treatment for geographic atrophy, at the American Society of Retina Specialists meeting. The data will help select patients for the ongoing Phase 3 ARCHER II trial, which completed enrollment in July ", "url": "https://www.investing.com/news/company-news/annexon-to-present-data-on-vonaprument-for-macular-degeneration-93CH-4791616", "source_name": "Investing.com", "published_at": "2026-07-14T20:16:05", "published_display": "14 Jul 2026 20:16", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026", "summary": "Annexon, Inc. announced an oral presentation at the American Society of Retina Specialists 44th Annual Scientific Meeting regarding the neuroprotective effect of vonaprument. The presentation will highlight baseline characteristics from the Phase 2 ARCHER trial associated with be", "url": "https://www.globenewswire.com/news-release/2026/07/14/3327265/0/en/annexon-to-present-phase-2-archer-baseline-characteristics-associated-with-confirmed-best-corrected-visual-acuity-15-letter-loss-in-patients-with-geographic-atrophy-at-asrs-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T20:12:20", "published_display": "14 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon to present baseline factors tied to 15-letter vision loss in AMD", "summary": "Annexon (NASDAQ: ANNX) is set to deliver an oral presentation at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, detailing Phase 2 ARCHER trial data for vonaprument in dry age-related macular degeneration (AMD) with geographic atrophy (GA). The p", "url": "https://www.stocktitan.net/news/ANNX/annexon-to-present-phase-2-archer-baseline-characteristics-7x0tnimvd7sl.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:12:20", "published_display": "14 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Annexon, Inc. SEC Filing", "summary": "This article details a Form 144 SEC filing by Annexon, Inc. (ANNX), indicating a proposed sale of securities. The filing shows a sale of 1000 common shares by an individual with Fidelity Brokerage Services LLC, acquired through a stock option exercise, with an aggregate market va", "url": "https://www.stocktitan.net/sec-filings/ANNX/144-annexon-inc-sec-filing-680ee3e00950.html", "source_name": "Stock Titan", "published_at": "2026-07-14T18:12:19", "published_display": "14 Jul 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon: Perfect Complement To A Speculative Biotech Portfolio (NASDAQ:ANNX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQOFgwd2hKMUY1Q2dQVTBtZFFCS1M5MkhqUHJyS3V1MzUxMDRNYjVycXp4R3QtQVUweXkwUVNqUXlLdHlFTzBkeW5HczI0R0xEMkJ6ZGtJUXZOcTEyQTV4cVI0Z05CWFY1SEZVY1k0SmdRVkxOMk9Fc0cydjZSYXJvcGZtSE9VTzVnS1E2VzBvVmdwMTU4X21FRGJadnVLWTN6T000VA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T09:43:52+00:00", "published_display": "14 Jul 2026 09:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Annexon stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQdDVtVFRkTkxSY2FsYzc2ald2RlVnQTdSRlJNNEhxbWJubmpfMkRlcmhZVXBndlZyX3BrVW5MZm5abmxUZnRPRmdPMDdBb045ZzhxUTdkRS1ZRndwNFlYWV9oUGQ1UXM5UHdTUGVtRzdoNkZkSjJOVVpwNklUM0hvZGpfdXdSdDJEYzVrZlpuYXI1NWp6M3AzWnc4c3Z4ZG9uWVB5X3FjT3BVVUl0OURpLW5SYjZuNjJU?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T14:38:13+00:00", "published_display": "13 Jul 2026 14:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Annexon, Inc. \u2013 NASDAQ:ANNX", "summary": "This article provides financial information for Annexon, Inc. (NASDAQ: ANNX), specifically focusing on its \"Price to book forward\" metric. The content appears to be a financial data page from TradingView, displaying the company's stock exchange listing and current market status. ", "url": "https://www.tradingview.com/symbols/NASDAQ-ANNX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T01:09:18", "published_display": "11 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Redmile Group (ANNX) reports 9.9% stake; RedCo II Offshore at 5.5%", "summary": "Redmile Group, LLC, and affiliated persons, including Jeremy C. Green, have reported a beneficial ownership stake of 9.9% in Annexon, Inc. (ANNX), comprising 17,918,459 shares. Additionally, RedCo II Offshore SPV LLC disclosed a 5.5% stake with 9,802,458 shares. These figures inc", "url": "https://www.stocktitan.net/sec-filings/ANNX/schedule-13g-a-annexon-inc-amended-passive-investment-disclosure-dd7dea6f78a8.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:40:49", "published_display": "09 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC reports 11.9% stake in Annexon (NASDAQ: ANNX)", "summary": "FMR LLC has filed a Schedule 13G/A, disclosing a beneficial ownership of 19,518,496.35 shares of Annexon (NASDAQ: ANNX) common stock, representing an 11.9% stake as of June 30, 2026. This filing indicates a passive investment intent, with FMR LLC holding sole dispositive power ov", "url": "https://www.stocktitan.net/sec-filings/ANNX/schedule-13g-a-annexon-inc-amended-passive-investment-disclosure-ae6ac97146ef.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:40:14", "published_display": "08 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "Annexon presented key updates on its clinical programs at the Goldman Sachs 47th Annual Global Healthcare Conference 2026, focusing on vonaprument for geographic atrophy (GA). The company anticipates pivotal Phase III data in Q4 2026, with vision preservation as the primary endpo", "url": "https://quartr.com/events/annexon-annx-goldman-sachs-47th-annual-global-healthcare-conference-2026_FLVYElEn", "source_name": "Quartr", "published_at": "2026-07-08T12:11:15", "published_display": "08 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Annexon\u2019s Shift Into Russell Growth Indices Recast Its Core Equity Story for Investors (ANNX)?", "summary": "Annexon, Inc. (ANNX) recently shifted from Russell value to growth indices in late June 2026, which impacts its perceived style profile and investor exposure. While this reclassification mainly affects who holds the stock, Annexon's core investment narrative remains focused on it", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-annx/annexon/news/does-annexons-shift-into-russell-growth-indices-recast-its-c", "source_name": "Simply Wall Street", "published_at": "2026-07-08T11:40:14", "published_display": "08 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANNX - Annexon Inc Options", "summary": "This page provides detailed financial and stock options information for Annexon Inc (ANNX). It includes key metrics such as market capitalization, income, sales, EPS, various financial ratios, insider and institutional ownership, and stock performance data. The data indicates rec", "url": "https://finviz.com/stock?t=ANNX&ty=oc&ta=1&p=m&ov=chain_date&e=2026-06-18", "source_name": "Finviz", "published_at": "2026-07-06T23:10:35", "published_display": "06 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $11", "summary": "Needham has reiterated its Buy rating for Annexon (ANNX.US) and maintained a target price of $11. This indicates continued confidence in the company's stock performance from the analyst firm.", "url": "https://www.moomoo.com/news/post/72399775/needham-maintains-annexon-annxus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-07-02T22:13:20", "published_display": "02 Jul 2026 22:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon, Inc.(NasdaqGS: ANNX) dropped from Russell 2000 Value Benchmark", "summary": "Annexon, Inc. (NasdaqGS: ANNX) has been removed from the Russell 2000 Value Benchmark. This news follows several recent re-benchmarking announcements, including its addition to the Russell 2500 Growth and Russell 2000 Growth Benchmarks, and also being dropped from the Russell Mic", "url": "https://www.marketscreener.com/news/annexon-inc-nasdaqgs-annx-dropped-from-russell-2000-value-benchmark-ce7f5fdfd88df724", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:09:26", "published_display": "29 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon, Inc. Actuals & Estimates (NASDAQ:ANNX)", "summary": "This article provides an overview of Annexon, Inc. (NASDAQ:ANNX) financial actuals and estimates, including its current stock price, market capitalization, and analyst forecasts. It also covers historical stock performance, earnings reports, and other key financial data. Investor", "url": "https://www.tradingview.com/symbols/NASDAQ-ANNX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:10:40", "published_display": "26 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon, Inc.'s (NASDAQ:ANNX) Profit Outlook", "summary": "This article analyzes the profit outlook for Annexon, Inc. (NASDAQ:ANNX) based on analyst forecasts. It discusses how the company is expected to transition from its current loss-making status to profitability and the projected financial performance over the coming years according", "url": "https://news.futunn.com/en/post/74965567/annexon-inc-s-nasdaq-annx-profit-outlook", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-24T19:39:51", "published_display": "24 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) Jefferies Global Healthcare Conference 2026 Summary", "summary": "This article summarizes Annexon's (ANNX) presentation at the Jefferies Global Healthcare Conference 2026, highlighting its strategic focus on pioneering C1q inhibition for neuroinflammatory diseases. Key points include late-stage development programs for Guillain-Barr\u00e9 syndrome (", "url": "https://quartr.com/events/annexon-inc-annx-jefferies-global-healthcare-conference-2026_FLVYElEG", "source_name": "Quartr", "published_at": "2026-06-22T17:09:54", "published_display": "22 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) AGM 2026 Summary", "summary": "Annexon's 2026 AGM summarized highlights from the company's annual meeting on June 11, 2026. Key points included a financial performance review indicating a cash runway into Q2 2027 and updates to the board and executive committee, noting the retirement of Tom Wiggans. The summar", "url": "https://quartr.com/events/annexon-inc-annx-agm-2026_FLVYEJqt", "source_name": "Quartr", "published_at": "2026-06-22T04:41:43", "published_display": "22 Jun 2026 04:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Inc (ANNX) Institutional Confidence", "summary": "This article examines the institutional confidence in Annexon Inc (ANNX) by detailing the shareholdings and activity of several major institutional investors. It highlights significant changes in holdings by firms like Redmile Group, Alerce Investment Management, and Adage Capita", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-annx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:46", "published_display": "18 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Inc (ANNX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Annexon Inc (ANNX), including analyst ratings, target prices, and EPS estimates. Based on 11 analysts, the stock has a \"Buy\" trend with a target price of $14.50, representing an upside of over 220%. The report also includes past and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-annx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:36:46", "published_display": "18 Jun 2026 02:36", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Inc (ANNX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Annexon Inc.'s (ANNX) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and reports no data available for historical dividend payments or stock splits. The page primarily fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-annx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:40", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Inc (ANNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Annexon Inc (ANNX), covering its support, resistance, indicators, and moving averages. According to the analysis, relevant data for support and resistance have not been disclosed, while the technical indicators show mixed signals with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-annx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T22:39:46", "published_display": "17 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (NASDAQ: ANNX) EVP exercises stock options, lifts stake to 184,807 shares", "summary": "Annexon, Inc. EVP Ted Yednock exercised stock options to acquire 30,646 common shares at an exercise price of $1.8501 per share on June 11, 2026. This transaction increased his direct ownership to 184,807 shares. The options were fully vested and exercisable, representing a routi", "url": "https://www.stocktitan.net/sec-filings/ANNX/form-4-annexon-inc-insider-trading-activity-aaa3edc97803.html", "source_name": "Stock Titan", "published_at": "2026-06-17T08:39:24", "published_display": "17 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new Annexon hires receive options on 705,000 shares", "summary": "Annexon (Nasdaq: ANNX) has granted stock options for 705,000 shares to two new non-executive employees under its 2022 Employment Inducement Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.64 per share, a ten-year term, and a", "url": "https://www.stocktitan.net/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-dn2okxqikwg4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:10:10", "published_display": "16 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) director William Waddill receives 65,000 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWG9oSENkSmt3bUpiTGZ0WXk3SDEyZHpXbmM4SGl5SmR0M3YxZEx3MkEybENGLUNMTTk0ald5aWdyUVBnbnlyNmh5bW82ZUVjRXNWektZa1lBZXVMTER4YkZWeHl4eE01NFdJRHpWZjY1NnZ4ODNpSS1oWG9ob3o5Y28tN3pzVnQzQXliNHZYY3puenpCWlVyQThPaVB3dXRVaDVvT2NXNFo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) grants director Jung Choi 65,000 stock options at $4.70", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPcjI0MU84LTJpYXRaZzk0cjJDYW5BTDJ2WnRBaFVpZlJrZGJqbzNieTdfR0w1XzA3eG1UUndWbldCQVN1emdyYk1TV3pKS1U3aFJGaldBSVNfLXhjbUJKZ05tRHJpc1A4NVhJS1ZWUDlRSE9jOElJdEx3M0lWQlRkWFJsSEpSLUhmb21iX2dvQXlxVk93MXZTb1k2M0JxT1V6UmlFTkR2cUc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX) director Bettina Cockroft awarded 65,000 stock options at $4.70", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOMi11RTVKU05ybGNVZkFPenRScURDS0NwOVluTWR0dE5fYjBhTWkwTVQ1VE5TZmo0T0M3WVYyMHVNd2U1TUNKd3E5X2dWMS1GVEpHbnppN3BnT3JHZmpCdWgzSi1xdGxCaUVRMk8xWUxScUdqUW52RmRnbE1aZk5aVVJDVC1HOVQxOW0yZ3EzZXJTNFJ6aEkzNmFkOWhDWWtGWkRTTFMyRXQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Eyes \u2018Win Season\u2019 With Q4 Vision Trial Data, GBS Filings Ahead", "summary": "", "url": "https://finance.yahoo.com/m/cc1b8a8c-417c-3307-86b7-ca1eade936f5/annexon-eyes-%E2%80%98win-season%E2%80%99.html", "source_name": "MarketBeat", "published_at": "2026-06-09T13:06:41+00:00", "published_display": "09 Jun 2026 13:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout", "summary": "", "url": "https://finance.yahoo.com/m/53971b69-6329-3d1f-a36f-1fb8267f5acb/annexon-maps-3-big-pipeline.html", "source_name": "MarketBeat", "published_at": "2026-06-04T07:07:07+00:00", "published_display": "04 Jun 2026 07:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Insider Bought Shares Worth $3,319,019, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/annexon-insider-bought-shares-worth-212921469.html", "source_name": "MT Newswires", "published_at": "2026-05-29T21:29:21+00:00", "published_display": "29 May 2026 21:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon to Participate in Upcoming June Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/news/annexon-participate-upcoming-june-investor-120000016.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T12:00:00+00:00", "published_display": "27 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon CEO Douglas Love to speak at Jefferies and Goldman Sachs in June", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQaDdGMGZ5a1pmME94QTAwb3kxeVY4M1lpOHI1Y1A5TWY2QXZGTFg0THRhWmNQbGpwbGhJNUF4V0J4bXdJTWpzdTl1VzlNZnQ5M0tqcXptMC12WFF6eEQwVVhzNnZVTHlVeGpnek8yLTVyVjZfSzk1eldlTFlmMGhxU1hiX3M2bXRIMkhFMi1QaUtLcVpWM2FMRmZNaFJxSFdDa0VzTDF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference", "summary": "", "url": "https://finance.yahoo.com/m/01b0e3a3-0fc9-342d-84c7-c9c2abf55d9b/annexon-highlights-q4.html", "source_name": "MarketBeat", "published_at": "2026-05-14T08:05:47+00:00", "published_display": "14 May 2026 08:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Initiates Annexon at Neutral With $7 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/goldman-sachs-initiates-annexon-neutral-112947244.html", "source_name": "MT Newswires", "published_at": "2026-05-12T11:29:47+00:00", "published_display": "12 May 2026 11:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxNU3dZcUI0ZHk2UFB5T2MyYXUzdEp3SGdPNnF6WGdrd3MtYWFwVVZkaVMxSDUwbWpyMldaM045MUFHcmFrUThLY0FtR0JiRWYzbl9MOWtTMmlDSHJIRTN1bk53VklMQlVFMXZTclAzOW9welBHdHQySHpmTF9odG9saGc5MHJpVUJBVTFIaU5qZlFLNDBSZ0dDbXdBNzlYTjkyTEpyRDdtMWZXZGk1dmx4dEpYdDdlakpNdVJWSmpqNTBFVThESjFOVEZ1TzV1UkRWVldzLUNtMlZCWlhxa19pZ29OVHg5eDlVRHFiS0VqUGRaSUpnU0pMRUhwaXNwUll3MVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon CEO to speak May 13; webcast replay stays up 30 days", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOLWRqdWZPcExzeHZlSDZPZ3VzQmV0OFY0a2lZRl9yZDRieEpId0xfLXR2aGY1dW1zWlM4aGFFelBlRm9Eanh3VHltMGRab0M3c1pfclNSbUlTb3E3WjlqYzdkMTZVVTJHa3FZWVZGWVVqVUxLbXdlRmVWZGo5VlNoZ2tEbkF6SDYwdGtoVmtPdk5NeHJHSVBWLVV5X0RBa25kRmZJZFJ2UlE3dUs3bWdyTFM2X05FMXZNaHVj?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPMjBZWjl4UGJXUW4xSmkzVVNEenN6eEJxbDNyV3d0S0xEb1dmRmtGMV9IeEFHQmxwZXo2a2hRd3QtcDhqRDdTMHJmeWJ1RGFuZU1PMzlSRUJzU1pINVJHd2Ffd0VZdjBEa2M3bFhGUl9SSnVhcTF6V2FIX21DX0JldlExNzVPa0dyZG9RQmJiN2UtbE0?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNMV93b1FHVzU5QzFhbEd0Ym1qQlZyRTBaOGVOT3lIMVhsV1kwNFVobWdUYU4wSXFYNXg4QVgyN2xzY2VqdXpNLS1XRjRuVF9feVY3TThheldGZU5PU1dId05CSkhYX0NrZUc1c191UEFpQ3gtcmhPU1FYQm14a3hHanF0V1N3d21yaVp4Y25DQ2pUb294bXhmT1BvZjN1dHBuNFV2RnZwYm1OM0lma1F1Q3F4N3hSS2xVQXNKVHVsQVFJbXU4TVo2RmxwWlZZUXN1OWJmTDdfRU5Tb2M?oc=5", "source_name": "Investing News Network", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQTmU1cG4xX2ZWX3RWV09pMVdhNjJqQnY4RXVPby1PLXR6Q3phQTN2T3hVeVBBSnhiTUdtLTBzZlBEWWtWTXR0cFRuVmcxdE43N2FKX2tPbTZpbVo5RG50TXRZVjMzX0QwWGVxWFpzaHBUMTl4bVY2Z1YtdnIxS2JwXzRJcDRsWVpxVkZWTk9QZ000Y0lCUDlHdVVxWVJidmVNb1o3eDVmN0tIWTVoQ3VRMGlwbmJyQ3dzeUx3YjZuWUY3QWl4andPanNuaWdlSUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 58, "sentiment_summary": {"positive": 20, "negative": 1, "neutral": 37, "score": 57, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 18.85, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 5.8, "latest_week": "2026-07-10", "one_week_move": 6.2, "four_week_move": 23.1, "twelve_week_move": -11.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.338908, "market_dynamics_buy_signal": false, "relative_strength": 13.124195, "fair_value_gap": 36.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.3798, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.2% over one week, +23.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "Market source", "count": 8}, {"label": "TradingKey", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "Quartr", "count": 3}, {"label": "MarketBeat", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 5}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+6.2% over one week, +23.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "How Investors Are Reacting To Annexon (ANNX) Phase 3 Tanruprubart Win And Vonaprument Updates"}], "updated_at": "2026-07-17T17:48:48.806566+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}